




May 1998:


Craig Venter launches private biotechnology company CELERA GENOMICS, Inc. and announces intention to sequence whole human genome in just 3 years and 300 mil. USD using the *wholegenome shotgun* approach.


The publicly funded HGP in that time: sequenced cca 4 % of the genome









































































Classification of eukaryotic genomic DNA:
Degree of condensation:
EuchromatinHeterochromatin (cca 10%, sequencing difficult)
 Repetitivity: Highly repetitive
 Moderately repetitive
 Non-repetitive (single-copy) Function:
 Structural (centromeres, telomeres) Coding protein
 Transcribed to noncoding RNA (introns, rRNA,
tRNA, miRNA etc.) Transposons
 Regulatory sequences Junk?
· JULIK:






























Comparison of human/mouse genome with genomes of lower organisms (C. elegans, Drosophila):


- expansion of gene families /new families related to:
 - blood clotting
 - acquired (specific) immunity
 - nervous system
 - intra- and intercellular communication
 - regulation of gene expression
 - programmed cell death (apoptosis)











Mobile (parasitic) elements in mammalian genome:

DNA transposons

 2-3 kb (or shorter), encode transposase, cut & paste or copy & paste in genome without RNA intermediate

Virus-like retrotransposons

 6-11 kb (or shorter), retroviruses without gene for protein envelope (env)

LINEs (long-interspersed repeats)

6-8 kb, e.g. L1, encode 2 proteins (one is reverse transcriptase)


SINEs (short-interspersed repeats)


 100-300 bp, e.g. Alu, code no protein, proliferation depends on LINEs, origin: small noncoding cellular RNA

Census of parasitic elements in human genome:			
LINEs:	850 000x	21 % genome	
SINEs:	1 500 000x	13 % genome	
Retrovirus-like:	450 000x	8 % genome	
DNA transposons:	300 000x	3 % genome	
 Mostly mutated and/or incomplete copies, only small part (<0,05%) still active: LINEs: 80-100 L1 SINEs: 2000-3000 Alu, <100 SVA Retrovirus-like: ? (HERV-Kreally extinct?) DNA transposons: 0 Mouse genome contains much more functional transposons (why?) 			

Significance of transposons in human genome

- Transposition in germinal cells is a rare event (approx. 1 new insertion per 20 live births, mostly Alu)
- Still a significant source of human genetic variability
- Can inactivate genes documented as a rare cause of inherited diseases
- In somatic cells can result in mosaicism
 - role of L1 in neurogenesis?





Non-classified "spacer" DNA:


non-repetitive, noncoding, >1/2 genome ... likely also dead transposons, too mutated to be recognizable


Project ENCODE, 2012: no junk DNA!


- Up to 80% of genome has biological function
- Up to 75% of genome is at least some time and somewhere transcribed to RNA


• Despite the fact that only 20% of genome at best is under evolutionary constraint





























Genomic medicine

2) Farmacogenomics – example:

Clopidogrel:

- Anticoagulans (blocks ADP receptor on thrombocytes)
- Pro-drug: Requires metabolic activation by microsomal hydroxylases (cytochrome P450 2C19)
- Up to 30% patients have genetically decreased or absent level of the activating enzyme 2C19

Study in patients with coronary stents:

- Choice of anticoagulant therapy guided by genotypization of CYP2C19: clopidogrel or ticagrelol/prasugrel
- Control group: ticagrelol/prasugrel
- Result: In genotype-guided group the therapy equally effective, but lower incidence of bleeding

Claasens et al. N. Engl. J. Med. 2019, 381:1621

